- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07610707
YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases
20 мая 2026 г. обновлено: Xingchen Peng, West China Hospital
A Phase I Clinical Trial of YMN-A02 in Patients With Advanced pMMR Colorectal Cancer and Liver Metastases: Safety, Tolerability, and Preliminary Efficacy
This study was a prospective, single-center, open-label, single-arm, multi-dose ascending phase Ⅰ clinical trial.
The investigators constructed a TM10-LNP mRNA preparation encoding CTLA-4 antibody and TGF-β trap bifunction protein (YMN-A02 bifunction RNA preparation).
The aim of this study is to provide a new strategy for overcoming the immune tolerance of liver tumors and improving the response rate of immunotherapy.
The investigators planned to enroll patients with advanced pMMR liver metastasis from colorectal cancer who failed standard treatment.
A modified "3+3" design was used, and 10 patients were expected to be enrolled.
There were four dose groups of 100μg, 250μg, 500μg and 1000μg.
The trial used a modified "3+3" dose climbing design, in which one subject was set as a sentinel patient in the initial 100μg dose group.
If the subject did not experience DLT during the DLT observation period, the dose was judged safe and escalation to the next group occurred.
If DLT occurred, 3 additional subjects in this group would be required for further evaluation.
In the subsequent 250μg, 500μg, and 1000μg dose groups, three subjects were enrolled first in each group: if there was no DLT, the number of subjects was increased.
If ≥2 of the 3 cases had DLT, the escalation was terminated.
If DLT occurred in 1 out of 3 subjects, 3 additional observations would be made in the same dose group.
If the incidence of DLT in the total 6 subjects did not exceed 1/6 after the supplement, the escalation could be escalated.
Otherwise, the escalation was terminated and the dose was considered as intolerable.
Обзор исследования
Статус
Еще не набирают
Тип исследования
Интервенционный
Регистрация (Оцененный)
10
Фаза
- Фаза 1
Контакты и местонахождение
В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.
Контакты исследования
- Имя: Peng Xingchen Peng
- Номер телефона: 86-17723609529
- Электронная почта: pxx2014@163.com
Места учебы
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610041
- West China Hospital
-
Контакт:
- Peng Xingchen Professor
- Номер телефона: 86-18980606753
- Электронная почта: pxx2014@scu.edu.cn
-
-
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Нет
Описание
Inclusion Criteria:
- Signed the informed consent form approved by the ethics committee.
- 18-70 years old; ECOG performance status 0-1.
- Histologically or cytologically confirmed colorectal cancer with liver metastases, molecularly classified as pMMR (presence of other distant metastases allowed).
Patients who have failed or are intolerant to standard therapy, or who refuse standard therapy.
- For patients with RAS/BRAF wild-type and eligible for targeted therapy: enrollment allowed only after disease progression on a prior standard regimen containing anti-EGFR or anti-VEGF monoclonal antibody.
- For patients with BRAF V600E mutation: enrollment allowed only after failure of a prior BRAF inhibitor-containing chemotherapy regimen.
- For patients who do not meet the above molecular characteristics: enrollment allowed only after failure of at least two prior lines of systemic chemotherapy (including a platinum-containing regimen).
- At least one measurable liver metastasis (CT scan long diameter ≥10 mm, slice thickness ≤5 mm).
- Life Expectancy≥3 months.
Adequate Major Organ Function (all within 14 days before randomization):
- Hemoglobin ≥80 g/L (no transfusion within 14 days); absolute neutrophil count >1.5×10⁹/L; platelet count ≥80×10⁹/L.
- Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN (or ≤5×ULN in the presence of liver metastases); creatinine clearance ≥60 mL/min (Cockcroft-Gault formula).
- Left ventricular ejection fraction (LVEF) ≥50%.
- Good compliance, and family agrees to cooperate with survival follow-up.
Exclusion Criteria:
- Participation in another interventional drug trial within 4 weeks before enrollment.
- Prior or concurrent other malignancy, except: carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, superficial bladder tumor, or any other malignancy that has been curatively treated and recurrence-free for ≥5 years.
- Poorly controlled heart disease or clinical symptoms, including but not limited to: NYHA class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
- Pregnant or breastfeeding women.
- Active infection, including but not limited to: active tuberculosis, systemic bacterial or fungal infection (NCI-CTCAE v5.0 grade ≥2), HIV infection, active HBV (HBV DNA >ULN), or active HCV (HCV RNA >ULN).
- History of substance abuse that cannot be abstained from, or history of psychiatric disorders.
- Active or history of autoimmune disease (including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism, etc.). Exceptions: vitiligo controlled with only topical agents; childhood asthma completely resolved without any intervention in adulthood. Patients with asthma requiring bronchodilators for medical intervention are excluded.
- Prior vaccination with any mRNA-based drug or mRNA formulation.
- Prior participation in any clinical trial involving lipid nanoparticle (LNP) formulations.
- Contraindications to intravenous infusion.
- History of drug abuse, or any medical, psychological, or social condition (e.g., alcoholism or drug addiction) that, in the investigator's judgment, may affect study compliance.
- Known allergy, hypersensitivity, or intolerance to any component (active substance or excipients) of the study drug; history of severe allergy to drugs, food, or vaccines, including but not limited to anaphylactic shock, angioedema of the larynx, anaphylactic dyspnea, allergic purpura, thrombocytopenic purpura, or Arthus reaction.
- Plan to conceive (either female subject or partner of male subject) from screening through 12 months after the last dose.
- Any concurrent condition that, in the investigator's judgment, may compromise patient safety or interfere with study completion.
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: YMN-A02 100 μg Group
Enrolled subjects will receive a 100 μg intravenous infusion.
|
Enrolled subjects will receive a 100 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
Другие имена:
|
|
Экспериментальный: YMN-A02 250 μg Group
Enrolled subjects will receive a 250 μg intravenous infusion.
|
Enrolled subjects will receive a 250 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
|
|
Экспериментальный: YMN-A02 500 μg Group
Enrolled subjects will receive a 500 μg intravenous infusion.
|
Enrolled subjects will receive a 500 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
|
|
Экспериментальный: YMN-A02 1000 μg Group
Enrolled subjects will receive a 1000 μg intravenous infusion.
|
Enrolled subjects will receive a 1000 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Occurrence of Dose-Limiting Toxicity (DLT)
Временное ограничение: From first dose to 14 days after the third dose, approximately Day 0 to Day 42
|
Observe and record the occurrence of DLTs.
DLT is defined as treatment-related adverse events or clinically significant laboratory abnormalities occurring during the DLT observation period, graded according to NCI CTCAE v5.0.
|
From first dose to 14 days after the third dose, approximately Day 0 to Day 42
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-Free Survival (PFS)
Временное ограничение: Within 2 years after the first dose
|
Assess disease progression per RECIST v1.1, calculating the time from start of treatment to first documented disease progression or death from any cause.
|
Within 2 years after the first dose
|
|
Objective Response Rate (ORR)
Временное ограничение: Within 6 months after the first dose
|
Tumor response assessed per RECIST v1.1 for solid tumors.
ORR is the proportion of patients whose tumor volume reduction reaches a predefined value and is maintained for a minimum required duration, calculated as the sum of complete response (CR) and partial response (PR) rates.
|
Within 6 months after the first dose
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Changes in Peripheral Blood Lymphocyte Subsets
Временное ограничение: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Peripheral blood lymphocytes will be isolated from whole blood using lymphocyte separation medium.
Flow cytometry will be used to detect T cells, B cells, macrophages, NK cells, and regulatory T cells (Tregs).
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
|
Percentage of Dendritic Cells Expressing Maturation/Activation Markers
Временное ограничение: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Dendritic cells (DCs) will be isolated from peripheral blood and labeled with antibodies against surface markers CD80, CD86, and MHC class II molecules.
Flow cytometry will be performed to determine the percentage of DCs positive for each marker.
Maturation and activation status are assessed based on these percentages
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
|
Tumor-Infiltrating CD8+ T Cells
Временное ограничение: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Tumor tissue sections will be stained to identify CD8+ T cells, including stem-like and exhausted CD8+ T cell subsets.
Confocal microscopy and flow cytometry (using single-cell suspensions from tumor tissue) will be used to observe the infiltration status of these cells.
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
|
Cytokine Levels Associated with Delayed-Type Hypersensitivity (DTH)
Временное ограничение: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Plasma will be collected 24-72 hours after administration.
ELISA kits will be used to measure the levels of cytokines including IL-12, IFN-γ, IL-2, and IL-10 to assess the cellular immune response and the impact of the product on immune function.
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Спонсор
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования (Оцененный)
30 июля 2026 г.
Первичное завершение (Оцененный)
30 июня 2028 г.
Завершение исследования (Оцененный)
30 июня 2028 г.
Даты регистрации исследования
Первый отправленный
26 апреля 2026 г.
Впервые представлено, что соответствует критериям контроля качества
20 мая 2026 г.
Первый опубликованный (Действительный)
28 мая 2026 г.
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
28 мая 2026 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
20 мая 2026 г.
Последняя проверка
1 мая 2026 г.
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- 2026(890)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕТ
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Нет
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Нет
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .